Branded Drug Makers Face Increasingly Aggressive Challenges By Generic Makers, Study Finds
Patent litigation remains the most commonly used generic defense strategy among makers of branded drugs, with 71% of drug companies reporting legal disputes to defend their patents in the past three years, according to research from pharmaceutical business intelligence firm Cutting Edge Information.
“The pharmaceutical industry faces a significant threat from generics companies who challenge existing patents and erode branded product sales. While patent defense constitutes...
To view the full article, register now.